References
- Braithwaite T, Vugler A, Tufail A. Autoimmune retinopathy. Ophthalmologica. 2012;228(3):131–142. doi:10.1159/000338240.
- Fox AR, Gordon LK, Heckenlively JR, et al. Consensus on the diagnosis and management of nonparaneoplastic autoimmune retinopathy using a modified Delphi approach. Am J Ophthalmol. 2016;168:183–190. doi:10.1016/j.ajo.2016.05.013.
- Comlekoglu DU, Thompson IA, Sen HN. Autoimmune retinopathy. Curr Opin Ophthalmol. 2013;24(6):598–605. doi:10.1097/ICU.0b013e3283654e1e.
- Ferreyra HA, Jayasundera T, Khan NW, He S, Lu Y, Heckenlively JR. Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol. 2009;127(4):390–397. doi:10.1001/archophthalmol.2009.24.
- Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Surv Ophthalmol. 2013;58(5):430–458. doi:10.1016/j.survophthal.2012.09.001.
- Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81(5):606–613. doi:10.1016/0002-9394(76)90125-2.
- Murphy MA, Thirkill CE, Hart WM. Jr Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neurophthalmol. 1997;17:77–83.
- Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol. 1999;117(4):471–477. doi:10.1001/archopht.117.4.471.
- Maleki A, Lamba N, Ma L, Lee S, Schmidt A, Foster CS. Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy. Clin Ophthalmol. 2017;11:377–385. doi:10.2147/OPTH.S120162.
- Forooghian F, MacDonald IM. Rituximab for the treatment of autoimmune retinopathy. Am J Ophthalmol. 2017;180:xv–xvi. doi:10.1016/j.ajo.2017.06.006.
- Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol. 2015;96(1):1–9. doi:10.1016/j.bcp.2015.04.008.
- Grange L, Dalal M, Nussenblatt RB, Sen HN. Autoimmune retinopathy. Am J Ophthalmol. 2014;157(2):266–272. doi:10.1016/j.ajo.2013.09.019.
- Kim SJ, Toma HS, Thirkill CE, Dunn JP Jr. Cancer-associated retinopathy with retinal periphlebitis in a patient with ovarian cancer. Ocul Immunol Inflamm. 2010;18(2):107–109. doi:10.3109/09273940903457441.
- Remulla JF, Pineda R, Gaudio AR, Milam AH. Cutaneous melanoma-associated retinopathy with retinal periphlebitis. Arch Ophthalmol. 1995;113:854–855.
- Moschos MM, Gouliopoulos NS, Kalogeropoulos C. Electrophysiological examination in uveitis: a review of the literature. Clin Ophthalmol. 2014;8:199–214. doi:10.2147/OPTH.S54838.
- Holder GE, Robson AG, Pavesio C, Graham EM. Electrophysiological characterisation and monitoring in the management of birdshot chorioretinopathy. Br J Ophthalmol. 2005;89(6):709–718. doi:10.1136/bjo.2004.047837.
- Matsui Y, Tsukitome H, Uchiyama E, et al. Peripheral capillary nonperfusion and full-field electroretinographic changes in eyes with frosted branch-like appearance retinal vasculitis. Clin Ophthalmol. 2013;7:137–140. doi:10.2147/OPTH.S40110.
- Fox A, Jeffrey B, Hasni S, Nussenblatt R, Sen HN. Rituximab treatment for nonparaneoplastic autoimmune retinopathy. Can J Ophthalmol. 2015;50(6):e101–4. doi:10.1016/j.jcjo.2015.08.009.
- Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016;4:CD010816.
- Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019;54(2):407–419. doi:10.3892/ijo.2018.4661.
- Grewal DS, Fishman GA, Jampol LM. Autoimmune retinopathy and antiretinal antibodies: a review. Retina. 2014;34(5):827–845. doi:10.1097/IAE.0000000000000119.
- Forooghian F, MacDonald IM, Heckenlively JR, et al. The need for standardization of antiretinal antibody detection and measurement. Am J Ophthalmol. 2008;146(4):489–495. doi:10.1016/j.ajo.2008.05.046.